Researchers tracked 87,935 patients’ EHRs throughout University of California Health, a six-hospital system, between 2014 and 2022. They evaluated medication fills for glucagon-like peptide-1 receptor agonists, which mimic a gut hormone that suppresses appetite and promotes a feeling of fullness.
The GLP-1s included in the study were Adlyxin, Byetta, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza and Wegovy. Only Saxenda and Wegovy are approved for weight management — the rest are Type 2 diabetes drugs.
During the first year each medication was available, the mean monthly growth rate was 85% for Ozempic, Wegovy, Rybelsus and Saxenda. Wegovy’s rate of growth was more than 100%, and Mounjaro’s exceeded 200% for the first seven months.
The researchers said the results show a “substantial shift in utilization patterns,” which could affect access — many GLP-1s indicated for Type 2 diabetes are currently in shortage — and disrupt the healthcare industry’s financial profile.
This monetary shift can go either way, since these products can cost about $1,000 for one patient’s monthly supply and most payers do not cover weight loss medications, thus increasing personal healthcare costs. On the other hand, “overweight and obesity-related medical costs are estimated at more than $92 billion annually in the United States,” the researchers wrote, meaning the sudden uptake of these therapies could result in lower medical costs for cardiovascular disease-related morbidity and mortality.
The study was conducted by researchers at the University of California-Irvine, and the results were published Oct. 10 in Science Direct.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.